The research team led by Lu Yingmei and Han Feng focuses on major diseases that pose a threat to human health, such as stroke, neurodegenerative diseases, autism, anxiety, and depression. They employ novel technologies, including transgenic model animals, in vivo electrophysiological recording, patch clamp, optogenetics, gene editing, and in vivo two-photon imaging, to investigate the pathogenesis and pharmacology of these conditions. They pay particular attention to the communication patterns among signal components within the neurovascular unit, aiming to facilitate the discovery of new drug targets and the development of innovative drugs.
